PepGuide

GLP-1 receptor agonist peptide

Semaglutide

A GLP-1 receptor agonist with strong human evidence for glycemic control and chronic weight management in approved populations.

Evidence:
Strong human evidence
Status:
FDA-approved for specific labeled indications
Reviewed:
2026-08-03

Also known as: Semaglutide, Sema, Ozempic, Wegovy, Rybelsus, GLP-1 RA, GLP-1, GL1SM

What is Semaglutide?

A GLP-1 receptor agonist with strong human evidence for glycemic control and chronic weight management in approved populations.

This profile is educational. It organizes publicly discussed research context for Semaglutide and related naming aliases — it is not a treatment guide.

Proposed mechanism

Activates GLP-1 receptors, enhancing glucose-dependent insulin secretion, suppressing glucagon, slowing gastric emptying, and reducing appetite via central and peripheral pathways.

Mechanism language on PepGuide describes how researchers discuss pathways. Proposed mechanisms can change as evidence evolves.

Current research notes

Human evidence grade: Strong human evidence

Preclinical evidence grade: Strong human evidence

GL1SM (semaglutide) is one of the best-characterized incretin peptides. STEP trials demonstrated ~15% mean weight loss at 68 weeks in adults with obesity (STEP 1, NEJM 2021). SUSTAIN and PIONEER programs established glycemic benefits in type 2 diabetes. FDA-approved for specific indications (e.g., Wegovy for chronic weight management, Ozempic for T2D). Researchers continue studying cardiovascular, renal, and MASH outcomes. Compounded or unapproved versions lack equivalent evidence and regulatory oversight.

Key uncertainties

  • Long-term maintenance after discontinuation
  • Pediatric and broader population data evolving

Research areas being studied

  • Obesity
  • Type 2 diabetes
  • Cardiovascular outcomes
  • MASH/NAFLD
  • CKD

Being studied for a topic is not the same as proven benefit in that topic. Prefer primary literature for study design, endpoints, and limitations.

Safety & side-effect notes

Reported or discussed adverse effects

  • Nausea
  • Vomiting
  • Diarrhea
  • Constipation
  • Abdominal pain

Additional risks & considerations

  • GI intolerance
  • Gallbladder events
  • Thyroid C-cell tumor warning (rodent data)
  • Pancreatitis (rare)

Regulatory status

FDA-approved for specific labeled indications

FDA approved for type 2 diabetes and chronic weight management under product-specific labeling.

Regulatory framing here is educational and can lag policy changes. Check official sources for current status.

Frequently asked questions

What is Semaglutide?

A GLP-1 receptor agonist with strong human evidence for glycemic control and chronic weight management in approved populations.

How does Semaglutide work (proposed mechanism)?

Activates GLP-1 receptors, enhancing glucose-dependent insulin secretion, suppressing glucagon, slowing gastric emptying, and reducing appetite via central and peripheral pathways.

What is Semaglutide being researched for?

Semaglutide has been discussed in research contexts including: Obesity, Type 2 diabetes, Cardiovascular outcomes, MASH/NAFLD, CKD.

What does current evidence say about Semaglutide?

Strong human evidence. GL1SM (semaglutide) is one of the best-characterized incretin peptides. STEP trials demonstrated ~15% mean weight loss at 68 weeks in adults with obesity (STEP 1, NEJM 2021). SUSTAIN and PIONEER programs established glycemic benefits in type 2 diabetes. FDA-approved for specific indications (e.g., Wegovy for chronic weight management, Ozempic for T2D). Researchers continue studying cardiovascular, renal, and MASH out…

What safety considerations are noted for Semaglutide?

Reported or discussed considerations include: Nausea; Vomiting; Diarrhea; Constipation; Abdominal pain; GI intolerance; Gallbladder events; Thyroid C-cell tumor warning (rodent data). This is educational information, not medical advice.

Is Semaglutide FDA approved?

FDA-approved for specific labeled indications. FDA approved for type 2 diabetes and chronic weight management under product-specific labeling.

References & sources

  • Wilding JPH et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1) — NEJM. Evidence type: human.
  • Lincoff AM et al. (2023). Semaglutide and Cardiovascular Outcomes (SELECT) — NEJM. Evidence type: human.

Prefer interactive tools? Open the PepGuide library entry for Semaglutide or ask PepGuide AI.

Educational and research information only. PepGuide does not sell or prescribe peptides, diagnose conditions, or provide personalized medical advice. Evidence summaries may include early-stage, animal, or limited human research — none of that is a substitute for primary literature or clinician guidance.